as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹945.1
Change
+0.8 (0.08%)
Open
₹933.5
Prev. Close
₹944.3
Day High
₹949.0
Day Low
₹933.5
Volume Analysis
Traded
9,934
Delivered
4,189
Delivery %
42.17%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (21.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹967.06 | ₹958.03 | ₹951.56 | ₹942.53 | ₹936.06 | ₹927.03 | ₹920.56 |
| Fibonacci | ₹958.03 | ₹952.11 | ₹948.45 | ₹942.53 | ₹936.61 | ₹932.95 | ₹927.03 |
| Camarilla | ₹949.36 | ₹947.94 | ₹946.52 | ₹942.53 | ₹943.68 | ₹942.26 | ₹940.84 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-25.15%
1 Week
+1.04%
1 Month
+0.54%
3 Months
-16.07%
6 Months
-24.46%
1 Year
-35.06%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹579.01
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.74%
Net margin 10.23% × asset turnover 0.48x × equity multiplier 3.41x
Company Overview
Sector
Chemicals
Market Cap
₹4,094 Cr
P/E (TTM)
14.4
ROE
16.0%
Book Value
₹548.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Epigral Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Chemicals sector, at 55/100. The strongest factor is Financial Strength (100/100), while Momentum (20/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); promoter holding is falling.
TopFund Score — Fundamentals Quality
55/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Debtor days have increased from 42.4 to 60.2 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Epigral Limited submits Transcript of conference call held on Monday, 2nd November, 2026 discussing Q2 FY2027 Results.
Epigral Limited submits a copy of newspaper publication pertaining to Un-Audited Financial Results for Second quarter and hald year ended 30.09.2026
Epigral shared the audio recording of its Q2 FY27 results conference call.
Q2FY27 PAT rose 26% to ₹64 Cr; revenue up 28% to ₹752 Cr, with expansions nearing commissioning.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 478 | 472 | 525 | 651 | 626 | 645 | 628 | 607 | 587 | 597 | 736 | 705 | 746 |
| Expenses + | 370 | 349 | 369 | 475 | 448 | 463 | 454 | 443 | 455 | 494 | 569 | 526 | 610 |
| Operating Profit | 108 | 123 | 155 | 176 | 178 | 183 | 173 | 163 | 132 | 103 | 168 | 179 | 136 |
| OPM % | 23.0% | 26.0% | 30.0% | 27.0% | 28.0% | 28.0% | 28.0% | 27.0% | 22.0% | 17.0% | 23.0% | 25.0% | 18.0% |
| Other Income + | 1 | 2 | 2 | 2 | 6 | 4 | 4 | 9 | 2 | 6 | -1 | 5 | 6 |
| Interest | 21 | 20 | 14 | 14 | 27 | 0 | 12 | 23 | 22 | 11 | 16 | 7 | 11 |
| Depreciation | 32 | 31 | 30 | 33 | 32 | 33 | 34 | 42 | 42 | 43 | 42 | 43 | 44 |
| Profit before tax | 56 | 74 | 113 | 131 | 125 | 154 | 131 | 107 | 70 | 55 | 110 | 134 | 88 |
| Tax % | 32.0% | 34.0% | 32.0% | 34.0% | 35.0% | 33.0% | 34.0% | -50.0% | 26.0% | 28.0% | 26.0% | 25.0% | 26.0% |
| Net Profit + | 38 | 49 | 77 | 86 | 81 | 104 | 87 | 161 | 51 | 39 | 81 | 100 | 65 |
| EPS in Rs | 9 | 12 | 19 | 21 | 20 | 24 | 20 | 37 | 12 | 9 | 19 | 23 | 15 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -14 | -12 | -7 | 43 | 31 | 37 | 20 | -7 | -6 | -7 | 17 | 16 | 27 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,527 | 2,785 |
| Expenses + | 245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,961 | 2,199 |
| Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 509 | 689 | 481 | 711 | 566 | 586 |
| OPM % | 38.0% | 37.0% | 42.0% | 43.0% | 32.0% | 32.0% | 33.0% | 31.0% | 25.0% | 28.0% | 22.0% | 21.0% |
| Other Income + | 2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 7 | 16 | 15 | 16 |
| Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 53 | 72 | 45 |
| Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 133 | 168 | 172 |
| Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 522 | 291 | 541 | 341 | 385 |
| Tax % | 23.0% | 11.0% | 20.0% | 25.0% | 21.0% | 37.0% | 34.0% | 32.0% | 33.0% | 34.0% | 3.0% | — |
| Net Profit + | 67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 358 | 332 | 285 |
| EPS in Rs | 9 | 9 | 22 | 44 | 27 | 24 | 61 | 85 | 47 | 83 | 77 | 66 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 6.0% | 11.0% | 7.0% | 6.0% | — |
| Sales growth | — | -1 | 52 | 19 | -14 | — | 87 | 41 | -12 | 32 | -1 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,861 | 2,178 | 2,322 |
| Borrowings + | 190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 593 | 572 | 570 |
| Other Liabilities + | 55 | 42 | 79 | 162 | 164 | 222 | 405 | 484 | 576 | 655 | 712 | 650 |
| Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 | 3,585 |
| Fixed Assets + | 364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,117 | 2,061 |
| CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 64 | 451 | 498 |
| Investments | 0 | 29 | 71 | 0 | 0 | 0 | 0 | 21 | 21 | 98 | 23 | 29 |
| Other Assets + | 106 | 98 | 173 | 281 | 142 | 221 | 467 | 450 | 524 | 752 | 915 | 997 |
| Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 | 3,585 |
| Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 43 | 43 | 43 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | — | — | — | 165 | 229 | 284 | 626 | 398 | 441 | 436 |
| Cash from Investing Activity + | — | — | — | — | -363 | -197 | -455 | -437 | -401 | -262 | -355 |
| Cash from Financing Activity + | — | — | — | — | 69 | -32 | 195 | -200 | -8 | -164 | -94 |
| Net Cash Flow | — | — | — | — | -129 | 1 | 24 | -11 | -11 | 15 | -14 |
| Free Cash Flow | — | — | — | — | -205 | 32 | -172 | 210 | -1 | 254 | 50 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | — | — | — | 99 | 99 | 68 | 106 | 93 | 78 | 90 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 27.37% | 27.1% | 26.75% | 25.12% | 23.71% | 23.34% | 23.3% | 23.52% | 23.67% | 24.71% | 24.56% | 25.27% |
| Promoters | 71.38% | 71.49% | 71.58% | 71.58% | 68.94% | 68.95% | 68.83% | 68.83% | 68.83% | 68.83% | 68.83% | 68.83% |
| Government | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| FII | 1.17% | 1.36% | 1.46% | 2.1% | 3.01% | 3.01% | 3.06% | 2.71% | 2.36% | 1.54% | 1.03% | 0.99% |
| DII | 0.05% | 0.02% | 0.18% | 1.17% | 4.31% | 4.66% | 4.78% | 4.93% | 5.13% | 4.9% | 5.56% | 4.89% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Chemicals — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Epigral Limited (this stock) | 4,094 | 14.4 | 1.73 | 16.0% |
| Steamhouse India Limited | 4,178 | 96.0 | 7.22 | 25.3% |
| Dhanuka Agritech Ltd | 4,010 | 13.3 | 2.28 | 20.5% |
| Laxmi Organic Indus Ltd | 4,190 | 24.4 | 1.99 | 4.11% |
| Ghcl Limited | 4,209 | 9.22 | 1.18 | 13.0% |
| Tatva Chin Pharm Chem Ltd | 3,937 | 61.6 | 4.84 | 5.54% |
| Chemplast Sanmar Limited | 3,888 | — | 2.46 | -6.8% |
Which Mutual Funds Hold Epigral Limited?
Frequently Asked Questions about Epigral Limited
Epigral Limited (EPIGRAL) closed at ₹945.1 on NSE on 19 November 2026, up 0.8 (0.08%) from the previous close.
Epigral Limited trades on the NSE (National Stock Exchange of India) under the symbol EPIGRAL.
Epigral Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 14.4.
Epigral Limited has a dividend yield of 0.53%.
Epigral Limited's 52-week high is ₹1,535.0 and its 52-week low is ₹806.0.
Epigral Limited has a market capitalisation of ₹4,094 crore.
Epigral Limited has a TopFund Quality Score of 55/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Epigral Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.